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Pentraxin 3 in primary
percutaneous coronary
intervention for STelevation
myocardial infarction is
associated with early irreversible
myocardial damage: Kinetic
profile, relationship to interleukin
6 and infarct size
Noreen Butt1,2, LK Bache-Mathiesen3, A Ushakova3,
JE Nordrehaug1,2, SE Jensen4, PS Munk5, N Danchin6,
JL Dubois-Rande7, HS Hansen8, F Paganelli9, P Le Corvoisier7,
H Firat10, D Erlinge11, D Atar12 and AI Larsen1,2
Abstract
Background: The inflammatory marker long pentraxin 3 (PTX3) has been shown to be a strong predictor of 30-day
and one-year mortality after acute myocardial infarction. The aim of this study was to evaluate the kinetic profile of
PTX3 and its relationship with interleukin 6 (IL-6), high-sensitive C-reactive protein (hs-CRP) and infarct size.
Methods: PTX3, IL-6 and hs-CRP were measured at predefined time points, at baseline (before percutaneous coronary
intervention (PCI)), at 12 and 72 hours after PCI in 161 patients with first-time STelevation myocardial infarction (STEMI).
Results: PTX3 and IL-6 levels increased in the early phase, followed by a gradual decrease between 12 and 72 hours.
There were statistically significant correlations between PTX3 and IL-6 in general, for all time points and for changes
over time (0–72 hours). In a linear mixed model, PTX3 predicted IL-6 (p< 0.001). PTX3 is also correlated with hs-CRP
in general, and at each time point post PCI, except at baseline. PTX3, IL-6 and hs-CRP were all significantly correlated
with infarct size in general, and at the peak time point for maximum troponin I. In addition, there was a modest
correlation between IL-6 levels at baseline and infarct size at 72 hours after PCI (q¼ 0.23, p¼ 0.006).
Conclusions: PTX3 had a similar kinetic profile to IL-6, with an early increase and decline, and was statistically
significantly correlated with markers of infarct size in STEMI patients post primary PCI. Baseline levels of IL-6 only
predicted infarct size at 72 hours post PCI.
Keywords
STEMI, primary percutaneous coronary intervention, pentraxin 3, interleukin 6, high-sensitive C-reactive protein, inflammation
Date received: 7 April 2020; accepted: 8 April 2020
1Department of Clinical Science, University of Bergen, Norway
2Department of Cardiology, Stavanger University Hospital, Norway
3Department of Research, Section of Biostatistics Stavanger, University
Hospital, Norway
4Cardiology, Aalborg University Hospital, Denmark
5Department of Cardiology, Sørlandet Hospital, Norway
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Introduction
Despite timely reperfusion by primary percutaneous
coronary intervention (pPCI) and optimal medical
treatment in patients admitted with ST elevation myo-
cardial infarction (STEMI), some patients develop
large infarcts with adverse left ventricular remodelling.
In addition to the reperfusion damage initiated by rad-
ical oxygen species, the extent of cardiac injury also
depends on the level of inflammation and subsequent
immune cell recruitment. An inflammatory phase dis-
proportionately prolonged, of excessive magnitude, or
insufficiently suppressed, can lead to sustained tissue
damage and improper healing, promoting infarct
expansion, adverse remodelling and chamber
dilatation.1
The MITOCARE trial evaluated whether the
administration of the mitochondrial permeability tran-
sition pore (mPTP) inhibitor TRO40303 prior to pPCI
could reduce reperfusion injury.2 However, the trial
failed to show a cardioprotective effect of the
substance.3
The secretion of interleukin 6 (IL-6), a prototypical
cytokine, which is the major determinant of the pro-
duction of the acute-phase proteins, C-reactive protein
(CRP; a short pentraxin), is increased in infarcted myo-
cardium.4 Moreover, elevated levels of both IL-6 and
CRP correlate with infarct size,5 and elevated levels of
CRP relate to increased in-hospital mortality and a
worse prognosis.6–11 The role of a relatively new bio-
marker in myocardial infarction, the long pentraxin 3
(PTX3), is less understood.12
Several cell types release PTX3 in response to
inflammation,13 and PTX3 is a more specific biomarker
of inflammation than CRP in atherosclerotic lesions.
Circulating levels of PTX3 reflect the instability of cor-
onary plaques and the extent of myocardial damage in
acute myocardial infarction (AMI).14 It is well known
that PTX3 is produced in response to inflammatory
cytokines like IL-6.15 However, few studies have eval-
uated the kinetic profile and the possible prognostic
significance of altered levels of PTX3 during STEMI.
This may be of clinical interest since PTX3 can have
protective anti-inflammatory properties. Moreover, it
is not known whether the level of inflammation at
admission before pPCI can predict infarct size.
The aims of the current study were as follows:
• To explore the kinetic profile of PTX3 and compare
it with the kinetic profile of IL-6 and hs-CRP in first-
time STEMI patients admitted for pPCI at prede-
fined time points.
• To investigate if the levels of these biomarkers are
associated with infarct size assessed by troponin
I (TnI) and creatine kinase–myocardial band (CK-
MB) at 72 hours post PCI.
• To evaluate whether hs-CRP and PTX3 can predict
the level of IL-6 during the first 72 hours post PCI.
Methods
Patients
The MITOCARE study was a multicentre, random-
ized, double-blind, placebo-controlled trial (RCT) car-
ried out in four European countries in the period
October 2011–September 2013. Details of the study
design have previously been reported.3 The study did
not show any beneficial effect of the mPTP inhibitor
TRO40303 in limiting the extent of reperfusion injury.
Briefly, the study population included patients> 18
years of age with a first-time STEMI, defined as nitrate-
resistant chest pain  30 min, and new ST elevation at
J-point in two contiguous leads with cut-off points: 
0.2 mV in men or  0.15 mV in women in leads V2–V3
and/or  0.1 mV in other leads. Additional inclusion
criteria were presentation within six hours of the onset
of chest pain, clinical decision to treat with pPCI,
occlusion of culprit artery with thrombolysis in myo-
cardial infarction (TIMI) flow grade 0–1 at time of
admission and before PCI. Patients were excluded if
they had multi-vessel disease, experienced cardiac
arrest with or without ventricular fibrillation, cardio-
genic shock, stent thrombosis, a previous AMI, angina
within 48 hours before infarction, previous coronary
artery bypass graft, intravenous fibrinolysis within 72
hours prior to PCI, atrial fibrillation, had a pacemaker,
concurrent inflammatory, infectious or malignant dis-
ease, or a biliary obstruction or hepatic insufficiency.
The demographics of the study population are shown
in Table 1.
A signed informed consent to participate was
obtained prior to any study-related procedure, or
within 12/24 hours post-procedure if oral consent was
provided beforehand (France/Norway). The study was
in accordance with the Declaration of Helsinki and
approved by the regional ethics committees.
Blood sampling and analyses
Blood samples from 161 patients were analysed by the
core lab FIRALIS (Huningue, France) to measure
levels of PTX3, IL-6 and hs-CRP, and markers of myo-
cardial necrosis CK-MB and TnI, before primary PCI
and at 12- and 72-hours post PCI. PTX3 was quantified
by use of a Human PTX3/TSG-14 Immunoassay
Quantikine ELISA Kit. To reduce measurement
errors, PTX3, IL-6 and hs-CRP were measured twice
at the respective time points. These repeated measures
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showed high internal consistency (Cronbach’s a> 0.9,
intraclass correlation coefficient> 0.9; online Appendix
Table 1).
Two patients did not undergo PCI and were
removed from the dataset. The patient flow chart is
shown in Figure 1.
We have previously shown that there were no statisti-
cally significant treatment effects of TRO40303 on the
levels of PTX3, IL-6 or hs-CRP during the first 72
hours after primary PCI16 (online Appendix Table 2).
Therefore, the kinetics of PTX3, IL-6 and hs-CRP were
analysed in all 161 patients. TnI and CK-MB were ana-
lysed as markers of myocardial injury at the same time
points as the inflammatory markers. Some patients had
missing values for one or more time points (online
Appendix Table 3). The detection method could not
detect values below a certain threshold, and some
values were removed due to measurement errors.
Statistical analysis
We used the average value of two measurements taken
at the same time for the correlation analysis for each
biomarker. Pearson’s correlation analyses were per-
formed between log-transformed values of PTX3, IL-
6 and hs-CRP in general, and for each time point at 0,
12 and 72 hours after PCI. Spearman’s correlations (q)
were analysed for changes in biomarkers over specific
time periods (0–72 h, 0–12 h and 12–72 h). The corre-
lation tests were repeated in the group of patients with
TIMI flow grade 3 after PCI to adjust for TIMI flow if
it was a potential confounder.
To assess whether there were relationships between
infarct size and levels of PTX3, IL-6 and hs-CRP,
Spearman’s correlations were evaluated between the
acute-phase proteins and the markers of infarct size
Figure 1. Patient flow chart.
Table 1. MITOCARE patient characteristics (n¼ 161).
Variable Frequency
Age, years, median (interquartile range) 62 (53, 70)
Body mass index (BMI), kg/m2,
median (interquartile range)
27.3 (25, 30)
Sex
Male 135 (83.9%)
Female 26 (16.1%)
Diabetes
Yes 12 (7.5%)
No 149 (92.5%)
Hypertension
Yes 47 (29.2%)
No 114 (70.8%)
Smoking
Yes 67 (46.2%)
No 78 (53.8%)
Stratum
Anterior 64 (39.8%)
Posterior 97 (60.2%)
Killip class
1 112 (70.4%)
2–5 47 (29.6%)
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(CK, CK-MB and TnI) in general and at specific time
points post PCI. Similarly, Spearman’s correlation
analyses were employed to assess the association
between the changes in levels of PTX3 and/or IL-6
and markers of infarct size.
To evaluate whether, and of what magnitude, the
amount of IL-6 can be predicted by levels of PTX3, a
linear mixed model was used. Mixed models are well
suited to control for within-cluster dependencies between
patients.17 Mixed models can also take into account
dependencies between repeated measurements. Thus,
the initial model included the random effects of (a) var-
iability between individuals in repeated measures; (b)
variability between individuals within the same centre;
(c) variability between values at different time points
within an individual; and (d) variability in the slope of
PTX3 between individuals. Selection of random effects
for the final model was determined by Akaike’s informa-
tion criterion (AIC). The correlation matrix structure
used in the model was compound symmetry.
The following effects were tested as potential con-
founders of the effect of PTX3 on IL-6: sex (male/
female), age (years), time (0/12/72 hours), smoking
(yes/no), hypertension (yes/no), diabetes (yes/no) and
stratum (anterior/posterior). The model with the most
accurate estimate of PTX3 was determined by the best
AIC. The Kenward–Roger approximated F-test was
used for estimation of p-values. Outlier influence was
evaluated with Cook’s Distance. PTX3 and IL-6 were
transformed by the natural logarithm. The same pro-
cedure was used to find out whether, and of what mag-
nitude, the amount of log-transformed IL-6 could be
predicted by levels of log-transformed hs-CRP.
A significance level of a¼ 0.05 was chosen for all
models and tests. The Statistical Package for the
Social Sciences (SPSS, Chicago, IL, USA) version 23
was used for correlations. R version 3.6, with the pack-
ages lme4 version 1.1-21, lmtest version 0.9-37, influ-
ence.ME version 0.9-9 and lmerTest version 3.1-1 were
used for mixed model estimations and model checking.
The package corrplot version 0.84 was used to create
correlation plots.
Results
Kinetics
In contrast to hs-CRP (Figure 2(c)), PTX3 and IL-6
levels increased in the early phase of first-time single-
vessel STEMI and then gradually decreased between 12
Figure 2. The kinetic profile of PTX3, IL-6, hsCRP, CK, CK-MB and TnI during the first 72 hours post PCI. Shown for levels of: (a)
PTX3; (b) IL-6; (c) hsCRP; (d) CK; (e) CK-MB; (f) TnI. Round points denote the median level of the corresponding biomarker at the
time measured; zero, 12 and 72 hours. Whiskers represent interquartile range.
PTX3: pentraxin 3; IL-6: interleukin 6; hsCRP: high-sensitive C-reactive protein; CK: creatinine kinase; CK-MB: creatine kinase–
myocardial band; TnI: troponin I.
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and 72 hours after PCI (Figure 2(a) and (b)). The same
pattern was seen for the markers of infarct size
(Figure 2(d) to (f)).
Correlation between pentraxins and IL-6
The correlations for all time points between PTX3,
IL-6 and hs-CRP are reported in Table 2. PTX3 and
IL-6 showed a weak but statistically significant corre-
lation at each time point (p< 0.05; Table 2).
This result was consistent with correlations between
changes of PTX3 and IL-6 from zero to 72 hours.
(p 0.001; Table 2, Figure 3). Hs-CRP was positively
correlated with IL-6 at each time point and with PTX3
at 12 and 72 hours (p< 0.001). However, there was no
significant association between hs-CRP and PTX3 at
zero hours (Table 2). There was a highly statistically
significant correlation between the changes in levels of
PTX3 and hs-CRP from 0 to 12 and 0 to 72 hours and
for IL-6 and hs-CRP at the same time intervals
(p< 0.001; Table 2, Figure 3). However, the correlation
between the changes in levels of PTX3 and IL-6 was
only statistically significant at 0–72 hours (p< 0.001;
Table 2, Figure 3). The correlation analyses performed
in patients with TIMI 3 flow only (n¼ 129) did not
substantially change the effect size or the levels of sta-
tistical significance for any of the correlations for the
whole cohort.
Infarct size
PTX3, IL-6 and hs-CRP were, to a varying degree,
significantly correlated with infarct size in general,
and at the peak time point of infarct size (Table 3).
IL-6 levels at baseline were statistically significantly,
but only modestly, correlated with markers of myocar-
dial injury (TnI) at 72 hours after PCI (q¼ 0.232,
p¼ 0.006; Table 3, Figures 4 and 5(c)); otherwise, nei-
ther PTX3 nor hs-CRP levels at baseline were related to
TnI or CKMB at 72 hours post PCI (Table 3, Figures 4
and 5(a), (b)).
Prediction of IL-6
Log-transformed values of hs-CRP and PTX3 were both
statistically significant predictors of log-transformed IL-
6 levels in the linear mixed model (hs-CRP: b¼ 0.28,
p< 0.001; PTX3: b¼ 0.25, p  0.001; Table 4).
Discussion
In the current study, levels of PTX3 increased during
the first 12 hours, followed by a decrease towards 72
hours post PCI. This is in contrast to the prolonged
increase known for hs-CRP. In addition, PTX3 was
associated with infarct size during the first 12 hours
of STEMI. This indicates that PTX3 is associated
with irreversible myocardial damage, supporting the
prognostic significance of admission and peak PTX3.
Moreover, IL-6 at baseline was a modest but statisti-
cally significant predictor of infarct size at 72 hours.
1) Kinetic profile of PTX3 compared with the kinetic
profile of IL-6 and hs-CRP in first-time single-vessel
STEMI
Pentraxins are essential components of the innate
immunity response and are divided into short pentrax-
ins such as CRP, mainly produced by liver cells in
response to IL-6 and long PTX3.15 Whereas both
CRP and PTX3 are well-known biomarkers of inflam-
mation and predict prognosis in cardiovascular dis-
ease,18,19 the long PTX3 differs from CRP, in gene
organization, chromosomal localization, cellular
Table 2. Correlation between pentraxin 3, interleukin 6 and hs-
CRP. Pearson correlations of log-transformed values in general
(overall), between baseline levels (0 hours), 12 and 72 hours post
PCI are calculated. For the change over time between these time
points (0–12 hours, 0–72 hours and 12–72 hours), Spearman
correlations are reported.
Pentraxin 3 IL-6 Hs-CRP
Overall
Pentraxin 3 1 0.36*** 0.22***
IL-6 0.36*** 1 0.40***
Hs-CRP 0.22*** 0.40*** 1
0 hours
Pentraxin 3 1 0.23* 0.05
IL-6 0.23* 1 0.29***
Hs-CRP 0.05 0.29*** 1
12 hours
Pentraxin 3 1 0.20* 0.30**
IL-6 0.20* 1 0.41***
Hs-CRP 0.30** 0.41*** 1
72 hours
Pentraxin 3 1 0.47*** 0.48***
IL-6 0.47*** 1 0.53***
Hs-CRP 0.48*** 0.53*** 1
0–12 hours
Pentraxin 3 1 0.18 0.33**
IL-6 0.18 1 0.31***
Hs-CRP 0.33** 0.31*** 1
0–72 hours
Pentraxin 3 1 0.33** 0.43***
IL-6 0.33** 1 0.38***
Hs-CRP 0.43*** 0.38*** 1
12–72 hours
Pentraxin 3 1 0.02 0.11
IL-6 0.02 1 0.29**
Hs-CRP 0.11 0.29** 1
*p< 0.05.
**p< 0.01.
***p< 0.001.
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sources and in the ability to induce stimuli and recog-
nize ligands.20
In contrast to hs-CRP, which seems to increase
beyond 72 hours, the current study showed that levels
of PTX3 (and IL-6) increased during the first 12 hours
and then decreased towards 72 hours post pPCI in first-
time STEMI patients. This is in accordance with pre-
vious research, indicating that plasma levels of PTX3
Figure 3. Correlation plot showing the magnitude and direction of correlations between changes in levels of PTX-3, IL-6 and hsCRP
from baseline to 72 hours. Greater size and colour intensity of circles indicates a higher correlation between markers in the
correlation plot.
PTX3: pentraxin 3; IL-6: interleukin 6; hsCRP: high-sensitive C-reactive protein.
Table 3. Spearman’s Rho (q) correlations between PTX3, IL-6, hs-CRP and markers of infarct size CK, CK-MB and TnI.
PTX3 IL-6 Hs-CRP
Overall
CK 0.31*** 0.48*** 0.21***
CK-MB 0.37*** 0.49*** 0.18***
TnI 0.36*** 0.55*** 0.38***
Peak time point (12 hours)†
CK 0.24* 0.32*** 0.33***
CK-MB 0.19* 0.26** 0.29***
TnI 0.26** 0.28*** 0.35***
PTX3, IL-6 and hs-CRP at baseline, infarct size after 72 hours§
CK 0.11 0.15 0.03
CK-MB 0.09 0.14 0.01
TnI 0.08 0.23** –0.02
*p< 0.05.
**p< 0.01.
***p< 0.001.
†The time point with the maximum median values for infarct size, CK, CK-MB and TnI.
§Whether values of PTX3, IL-6 and hs-CRP at baseline are correlated with markers of infarct size 72 hours post PCI.
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seem to be normalized within 48 hours after the onset of
symptoms.21 The fast increase is depending on the
release of PTX3 from granules in neutrophil leucocytes,
which occur within six hours after plaque rupture in
AMI. The subsequent gradual decline after the peak of
12 hours is, on the other hand, mostly due to the short
half-life of the circulating neutrophil granulo-
cytes.12,21,22 On the contrary, CRP is produced in the
liver cells stimulated by IL-6. The kinetic profile previ-
ously described for CRP is in accordance with the cur-
rent study in which the actual measurements were done
at zero, 12 and 72 hours.
Mechanisms of action of PTX3. After reperfusion injury,
the lack of PTX3 has been shown to be associated with
increased myocardial damage, characterized by no-
reflow area, increased neutrophil infiltration, increased
number of apoptotic cells and decreased number of
capillaries. In addition, C3 complement component
has been shown to increase focally, being related to
the area of damaged myocardium. In PTX3 knock-
out mice, the administration of exogenous PTX3
reduces complement C3 deposition, further indicating
cardioprotective effects of PTX3 by the modulation of
the complement cascade.23
The released PTX3 also binds to activated circulat-
ing platelets, resulting in the reduction of their pro-
inflammatory and prothrombotic effects,21 supporting
the view that PTX3 also have atheroprotective
effects.24 The physiological properties and role of
PTX3 are not fully understood, but current evidence
support that PTX3 might have both pro-inflammatory
and anti-inflammatory effects depending on the context
of the action.13
2) Prognostic importance of PTX3, IL-6 and hs-CRP
Despite these potentially beneficial effects of PTX3,25–
27 elevated levels are associated with the magnitude of
myocardial damage. In addition, high PTX3 levels are
a predictor for increased morbidity and mortality in
STEMI patients undergoing pPCI.28–30 A positive cor-
relation between levels of PTX3, CRP and
metalloproteinase-9, also underline the importance of
PTX3 on prognosis in this population.31,32 PTX3, IL-6
and CRP all have prognostic value in AMI. Ammirati
et al. proposed a risk index that combines IL-6 with
Figure 4. Correlation plot showing the magnitude and direction of correlations between PTX3, IL-6 and hsCRP levels at baseline
and markers of infarct size, TnI, CK and CK-MB levels, 72 hours post PCI. Greater size and colour intensity of circles indicates a
higher correlation between markers in the correlation plot.
PTX3: pentraxin 3; IL-6: interleukin 6; hsCRP: high-sensitive C-reactive protein; CK: creatinine kinase; CK-MB: creatinine kinase–
myocardial band; TnI: troponin I; PCI: percutaneous coronary intervention.
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Figure 5. Scatterplots showing the relationship between (a) PTX-3 levels at baseline and TnI levels 72 hours post PCI; (b) baseline IL-
6 and TnI levels 72 hours post PCI; (c) baseline hsCRP and TnI levels 72 hour post PCI.
PTX3: pentraxin 3; IL-6: interleukin 6; hsCRP: high-sensitive C-reactive protein; TnI: troponin I; PCI: percutaneous coronary
intervention.
Table 4. Coefficient estimate b and Kenward–Roger p-values estimated from a linear mixed model to determine whether levels of
pentraxin 3 can predict levels of interleukin 6, and, likewise, for whether hs-CRP can predict levels of IL-6.
Model with pentraxin 3 Model with hs-CRP
Fixed effects Estimates (95% CI) P-value† Fixed effects Estimates (95% CI) P-value†
Intercept 0.02 (–0.55, 0.6) 0.932 Intercept –0.51 (–0.98, –0.04) 0.034
log pentraxin3* 0.25 (0.14, 0.36) <0.001 log hs-CRP* 0.28 (0.21, 0.35) <0.001
Age (years) 0.01 (0.00, 0.02) 0.115 Age (years) 0.01 (0.00, 0.01) 0.070
Sex Sex
Female 0 Female
Male 0.21 (–0.06, 0.48) 0.124 Male 0.13 (–0.10, 0.36) 0.275
Time Time
0 0 0
12 0.91 (0.73, 1.09) <0.001 12 0.8 (0.64, 0.95) <0.001
72 0.61 (0.44, 0.79) <0.001 72 –0.04 (–0.25, 0.16) 0.674
*Interleukin 6, pentraxin 3 and hs-CRP were transformed by the natural logarithm for this model.
†Based on Kenward–Roger F-test.
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IL-10 to predict outcome in STEMI patients.33 The
effect on prognosis is partly related to an effect on
remodelling.
Myocardial necrosis and inflammation; the role of pentraxins’
relationship to prognosis. It is well recognized that elevat-
ed levels of circulating IL-6 in acute coronary syn-
dromes are of prognostic value.34–36 IL-6 binds to
plasma membrane receptor complexes in the heart,
activating two major signalling cascades, SHP2/ERK
and STAT pathways that are important for the remod-
elling process in the myocardium.37
In accordance with this, a relationship between IL-6
and the end-diastolic diameter of the left ventricle at
long-term follow-up has been demonstrated.38 In addi-
tion, both circulating levels of IL-6 and CRP have
shown to be associated with the extent of myocardial
necrosis.39
In contrast to the current findings, an experimental
model has demonstrated that low levels of PTX3 were
associated with high levels of IL-6 and extended myo-
cardial damage. This was related to the ischemia-
reperfusion injury, in that PTX3 deficient mice develop
increased myocardial damage, characterized by no-
reflow area, increased neutrophil infiltration apoptotic
cells and decreased number of capillaries.23 The coro-
nary circulation is the main source of PTX3 in heart
failure patients with normal ejection fraction, and
levels of PTX3 correlate with the degree of left ventric-
ular diastolic dysfunction.40 This identification of myo-
cardial tissue as a main source for circulating levels of
PTX3 indicates that PTX3 is an early marker of irre-
versible myocyte injury in ischemic cardiomyopathy.
Systemic pre-PCI levels of PTX3 have been shown to
be associated with high-risk plaque components and
impaired post-PCI myocardial perfusion.30 It has,
therefore, been speculated that PTX3 might act as a
potential novel biomarker of myocardial infarction.
Accordingly, in the current study we found that
PTX3, IL-6 and hs-CRP are correlated with markers
of myocardial necrosis during the first 12 hours of myo-
cardial infarction (Table 4). Moreover, there was a sta-
tistically significant correlation between PTX3 and IL-6
at all time points, but no statistically sigificantly corre-
lation between PTX3 and hs-CRP at baseline (Table 2)
hs-CRP. This relationship is further confirmed in the
finding that both PTX3 and hs-CRP could predict IL-6
response (Tables 3 and 4).
In the current study, we found that IL-6 at baseline
was a modest but statistically significant predictor of
infarct size at 72 hours. This may indicate that the level
of inflammation at baseline is an important factor for
infarct size and subsequent left ventricular function and
prognosis. Thus, PTX3, IL-6 and CRP all have prog-
nostic value in AMI.
Study strengths and limitations. The weakness of the study
is the few time points for analysis. In addition, the time
from symptom debut to admission is often difficult to
assess and confirm. On the other hand, the strength of
the current study is the prospective design with blood
samples drawn at specific pre-defined time points. The
blood samples were immediately processed and stored.
The population is relatively homogenous with first-time
STEMI, with the occlusion of one of the major coro-
nary branches. The inclusion criteria excluded patients
with symptoms beyond six hours. The study was a
multicentre RCT, with all analyses performed at one
core lab.
Conclusion
In first-time STEMI patients post primary PCI, PTX3
and IL-6 had a similar kinetic profile with an early
increase and decline in contrast to the pattern seen
for hs-CRP. In addition, levels of PTX3 were statisti-
cally significantly correlated with markers of infarct
size. Finally, the infarct size at 72 hours post PCI was
predicted only by baseline levels of IL-6 and not base-
line levels of PTX3.
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